Cargando…
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report
BACKGROUND: In general, dexamethasone is a required component drug in various combination chemotherapies for treating multiple myeloma, and its efficacy has been widely recognized. However, administration of dexamethasone is known to cause various adverse effects including hyperglycemia which requir...
Autores principales: | Takemori, Nobuo, Imai, Goro, Hoshino, Kazuo, Ooi, Akishi, Kojima, Masaru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816938/ https://www.ncbi.nlm.nih.gov/pubmed/29454372 http://dx.doi.org/10.1186/s13256-017-1550-6 |
Ejemplares similares
-
Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma
por: Takemori, Nobuo, et al.
Publicado: (2020) -
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017) -
Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report
por: Takemori, Nobuo, et al.
Publicado: (2014) -
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018) -
Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration
por: Takemori, Nobuo, et al.
Publicado: (2012)